Viatris Pty Ltd Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Viatris Pty Ltd Pharmaceutical Import Records from India — 2 Products, $659.8K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Viatris Pty Ltd — Pharmaceutical Importer Profile (2026) | 2 Products, $659.8K Trade | TransData Nexus

Viatris Pty Ltd

Pharmaceutical Importer · Australia · Respiratory Focus · $659.8K Total Trade · DGFT Verified

Viatris Pty Ltd is a pharmaceutical importer based in Australia with a total trade value of $659.8K across 2 products in 2 therapeutic categories. Based on 15 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Viatris Pty Ltd sources from 6 verified Indian suppliers, with Cipla Limited accounting for 29.3% of imports.

Viatris Pty Ltd — Import Portfolio & Supplier Network

Viatris Pty Ltd import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Viatris Pty Ltd?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$1.3M	105	29.3%
Micro Labs Limited	$1.2M	40	28.1%
Mylan Laboratories Limited	$812.6K

What Formulations Does Viatris Pty Ltd Import?

Formulation	Value	Ships
Dymista allergy (azelastine hydrochloride 137mcg+fluticasone propionate 50mcg)	$300.0K	6
Cilicaine vk 500 (phenoxymethylpenicilli	$258.0K	7
Dymista allergy (azelastine 125 microgram(as hydrochloride)and fluticasone propionate 50mcg nasal spray-au otc	$200.0K	4
Dymista allergy (azelastine 125 microgram(as hydrochloride)and fluticasone propionate 50mcg nasal spray-au	$200.0K	4
Cordilox sr 240MG 2x15tabs au (2 x 15'sblister)	$182.6K	6
Dymista allergy (azelastine 125 microgram(as hydrochloride)andfluticasone propionate 50mcg nasal spray -au	$150.0K	3
Cordilox sr 240 MG 2x15 tabs packs	$100.0K	2
Dymista allergy (azelastine 125 microgram(as hydrochloride)and fluticasone propionate 50mcg nasal spray -au	$100.0K	2
Cilicaine vk 250 (phenoxymethylpenicilli	$98.1K	2
Periactin 4MG tablets(cyproheptadine	$96.3K	4
Cilicaine vk 500 (phenoxymethylpenicilli	$90.4K	2
Cilicaine vk 500(phenoxymethylpenicillin	$81.2K	3
Aspecillin phenoxymethylpenicillin 500MG(phenoxymethylpenicillin tablets 500MG BP)25s(qty:46625)tax inv	$59.7K	3
Isoptin sr 240MG 30bl (2 x 15's blister)	$57.7K	2
Periactin tablets 4MG(cyproheptadine	$50.6K	3

Viatris Pty Ltd imports 136 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Fluticasone	Respiratory	$650.0K	13	0.3%	10
2	Brufen	Brand Names & OTC Products	$9.8K	2	0.2%	18

Viatris Pty Ltd imports 2 pharmaceutical products across 2 categories into Australia totaling $659.8K.

Viatris Pty Ltd — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Viatris Pty Ltd is an Australian pharmaceutical company headquartered in Sydney, New South Wales. Established in 2014, it operates as a proprietary company, limited by shares, and is registered for Goods and Services Tax (GST) purposes. The company is a subsidiary of Viatris Inc., a global healthcare corporation formed in 2020 through the merger of Mylan and Upjohn, a legacy division of Pfizer. (viatris.com.au) Viatris Pty Ltd plays a significant role in Australia's pharmaceutical distribution network, providing access to a broad range of high-quality, trusted medicines across various therapeutic areas. (viatris.com.au)

2Distribution Network

Viatris Pty Ltd operates a robust distribution network within Australia, with a state-of-the-art warehouse and distribution centre located in Bundamba, Queensland. This facility, equivalent in size to 43 Olympic pools, stores extensive volumes of stock and a wide range of critical products under one roof. Orders can be made from this warehouse and shipped anywhere around the country overnight, ensuring timely delivery to meet the healthcare needs of Australians. (viatris.com.au) Additionally, Viatris Pty Ltd exports medicines to over 40 countries, leveraging its global manufacturing and distribution capabilities to reach a broader market. (viatris.com.au)

3Industry Role

Viatris Pty Ltd serves as a primary wholesaler in Australia's pharmaceutical supply chain. The company imports a diverse portfolio of medicines, including prescription drugs, over-the-counter (OTC) products, and generics, to meet the healthcare needs of the Australian population. By partnering with healthcare professionals, government bodies, and patient groups, Viatris Pty Ltd ensures the availability of affordable, high-quality medicines across the country. (viatris.com.au)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Viatris Pty Ltd

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Viatris Pty Ltd's sourcing strategy exhibits a high degree of concentration, with a total import value from India amounting to $660,000 USD across 15 shipments. The top five products imported are Fluticasone ($650,000 USD) and Brufen ($10,000 USD), accounting for 98.5% and 1.5% of the total import value, respectively. This concentration indicates a strategic choice to focus on specific products, potentially leveraging favorable pricing or supplier relationships. However, such dependency on a limited number of products and suppliers may pose risks related to supply chain disruptions or changes in market demand. The shipment data reveals a stable relationship with Indian suppliers, as evidenced by the consistent import volumes over the period.

2Supply Chain Resilience

Viatris Pty Ltd's supply chain resilience is supported by its partnerships with multiple Indian suppliers, including CIPLA Limited, Micro Labs Limited, Mylan Laboratories Limited, Medreich Limited, Sharon Bio-Medicine Limited, and Intas Pharmaceuticals Limited. This diversified supplier base enhances the company's ability to mitigate risks associated with single-source dependency. The importation of 136 unique formulations further demonstrates the company's commitment to offering a broad range of products to meet diverse patient needs. While the supply chain appears robust, ongoing monitoring of supplier performance and market conditions is essential to maintain resilience.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the Therapeutic Goods Administration (TGA) is the primary regulatory authority responsible for overseeing the importation, manufacturing, and distribution of therapeutic goods, including pharmaceuticals. The TGA operates under the Therapeutic Goods Administration Act 1989, which outlines the regulatory framework for ensuring the safety, efficacy, and quality of medicines available in Australia. For Indian generics to be marketed in Australia, they must undergo the TGA's evaluation process, which includes assessment of the product's quality, safety, and efficacy, as well as compliance with Australian labeling and packaging requirements.

2Import Licensing & GMP

Import licensing in Australia is governed by the TGA, which requires that all imported therapeutic goods be included in the Australian Register of Therapeutic Goods (ARTG) before they can be supplied in the country. Manufacturers and suppliers must provide evidence of Good Manufacturing Practice (GMP) compliance, typically through certificates from recognized authorities such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications ensure that the manufacturing processes meet international standards for quality and safety. Additionally, wholesalers like Viatris Pty Ltd must hold a valid wholesale distribution authorization issued by the TGA to legally distribute therapeutic goods within Australia.

Viatris Pty Ltd — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Viatris Pty Ltd's product strategy focuses on therapeutic areas with high demand and significant patient impact, such as respiratory conditions. The company's importation of Fluticasone, a corticosteroid used to treat asthma and allergic rhinitis, aligns with this focus. The substantial import value of Fluticasone indicates a strong market demand and the company's commitment to providing effective treatments for respiratory conditions. The inclusion of Brufen, a nonsteroidal anti-inflammatory drug (NSAID) used for pain relief, suggests a strategic approach to offering a comprehensive range of therapeutic options to meet diverse patient needs.

2Sourcing Profile

Viatris Pty Ltd's sourcing strategy emphasizes the importation of generic drugs, leveraging cost-effective manufacturing processes to provide affordable medicines to the Australian market. The company's focus on finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, indicates a preference for ready-to-use products that meet the therapeutic needs of patients. India's established pharmaceutical industry, with its adherence to international GMP standards, positions it as a key supplier for Viatris Pty Ltd's procurement needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to Viatris Pty Ltd

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Viatris Pty Ltd, particularly if they can offer high-quality generic products that align with the company's therapeutic focus areas. Gaps in Viatris Pty Ltd's current sourcing may exist in specific therapeutic categories or formulations not currently covered. Indian exporters can explore these opportunities by ensuring compliance with Australian regulatory requirements and demonstrating the quality and efficacy of their products.

2Requirements & Qualifications

Indian exporters seeking to supply Viatris Pty Ltd and the Australian market must obtain GMP certifications from recognized authorities such as the EU, WHO, or PIC/S. They must also ensure that their products are included in the ARTG and comply with Australian labeling and packaging standards. Additionally, maintaining a consistent supply of high-quality products and adhering to agreed-upon delivery schedules are essential to meet the expectations of Viatris Pty Ltd and the Australian market.

3How to Approach

Frequently Asked Questions — Viatris Pty Ltd

What products does Viatris Pty Ltd import from India?

Viatris Pty Ltd imports 2 pharmaceutical products across 2 categories. Top imports: Fluticasone ($650.0K), Brufen ($9.8K).

Who supplies pharmaceuticals to Viatris Pty Ltd from India?

Viatris Pty Ltd sources from 6 verified Indian suppliers. The primary supplier is Cipla Limited (29.3% of imports, $1.3M).

What is Viatris Pty Ltd's total pharmaceutical import value?

Viatris Pty Ltd's total pharmaceutical import value from India is $659.8K, based on 15 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Viatris Pty Ltd focus on?

Viatris Pty Ltd imports across 2 categories. The largest: Respiratory (98.5%), Brand Names & OTC Products (1.5%).

Get Full Viatris Pty Ltd Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.